Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

J&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

强生(JNJ.US)周五宣布，计划在未来四年将其在美国的投资增加到550亿美元以上，比前四年增长25%。 除了位于北卡罗来纳州威尔逊的工厂外，该公司增加的投资还涵盖三个新的先进制造工厂，以及其创新医学和医疗技术业务的多个现有工厂的扩建。 强生还计划对研发基础设施进行大量投资，并加大技术投资以加快药物发现和开发。 随着投资的增加，强生对美国经济的影响将在目前预计的每年超过1000亿美元的基础上进一步 ...

JOHNSON & JOHNSON (JNJ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s ...

The latest trading day saw Johnson & Johnson (JNJ) settling at $163.29, representing a -0.21% change from its previous close.

Bank of America is bullish on Johnson & Johnson and Clorox stocks. Analysts at the firm expect JNJ and CLX to do well amidst ...

JOHNSON & JOHNSON (JNJ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s ...

Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for ...

智通财经APP获悉，2025年3月17日，强生 (JNJ.US)在Clinicaltrials.gov网站上注册了IL-23R口服环肽抑制剂JNJ-2113 (Icotrokinra)治疗银屑病关节炎的三期临床试验ICONIC-PsA 1。该三期临床试验计划入组540例银屑病关节炎患者，预计2026年初步完成。

Johnson & Johnson (JNJ) announced its plans to invest over $55 billion over the next four years in the U.S. to strengthen its ...